Adjuvant compounds
US9370557B2 · kind B2 · utility
0Cited by
2References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 15, 2007 |
| Grant date | Jun 21, 2016 |
| Priority date | — |
| Expiry date | Nov 21, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/6068
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the use of bacterial cytolysin proteins, such as pneumolysin, as adjuvants for stimulating or enhancing immune responses against co-administered target antigens. Desirably, the target antigen is provided as a fusion protein with the cytolysin. The inventors have found that cytolysins may be particularly effective for stimulation of mucosal immune responses against the target antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.